

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

SECOND SUPPLEMENTAL PLACING AGREEMENT RELATING TO PLACING OF CONVERTIBLE BONDS UNDER GENERAL MANDATE

References are made to (i) the announcement of China Biotech Services Holdings Limited (the “**Company**”) dated 25 March 2024 in relation to the placing of Convertible Bonds under General Mandate (the “**Placing Announcement**”); and (ii) the announcement of the Company dated 27 March 2024 in relation to the supplemental placing agreement to the Placing Agreement (the “**First Supplemental Placing Agreement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Placing Announcement.

As additional time is required for the Placing Agent to procure investors to subscribe for the Convertible Bonds, the Company and the Placing Agent entered into a second supplemental placing agreement to the Placing Agreement on 15 April 2024 (the “**Second Supplemental Placing Agreement**”), pursuant to which the Company and the Placing Agent agreed to, among other things, extend the Long Stop Date from 15 April 2024 to 30 April 2024 (or such later date as may be agreed between the Placing Agent and the Company in writing). As a result of the entering into the Second Supplemental Placing Agreement, the First Supplemental Placing Agreement has been superseded.

Save as aforesaid, all other terms and conditions of the Placing Agreement shall remain unchanged and shall continue to be in full force and effect. The Company will keep its shareholders and potential investors informed of any significant development of the Placing and will make further announcement(s) as and when appropriate in accordance with the GEM Listing Rules.

Shareholders of the Company and potential investors should accordingly exercise caution when dealing in the securities of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 15 April 2024

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.